Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 220 000 KRW 2.8% Market Closed
Market Cap: 50.8T KRW
Section:
 

Relative Value

The Relative Value of one Celltrion Inc stock under the Base Case scenario is 237 642.69 KRW. Compared to the current market price of 220 000 KRW, Celltrion Inc is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
237 642.69 KRW
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

12.4
P/S
P/S
Price to Sales
12.4
vs History
42
vs Industry
37
Median 3Y
10.2
Median 5Y
11.5
Industry
8.2
Forward
11.4
More Details
65.2
P/E
P/E
Price to Earnings
65.2
vs History
42
vs Industry
0
Median 3Y
67.8
Median 5Y
58.9
Industry
24.2
Forward
55.7
More Details
59.3
P/OCF
P/OCF
Price to OCF
59.3
vs History
49
vs Industry
3
Median 3Y
50.1
Median 5Y
57.4
Industry
23
More Details
143.9
P/FCFE
P/FCFE
Price to FCFE
143.9
vs History
19
vs Industry
1
Median 3Y
87.1
Median 5Y
67.1
Industry
25.5
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
58
vs Industry
37
Median 3Y
2.4
Median 5Y
5.1
Industry
3.3
More Details
12.8
EV/S
EV/S
Enterprise Value to Sales
12.8
vs History
41
vs Industry
31
Median 3Y
10.5
Median 5Y
11.6
Industry
8.6
Forward
11.9
More Details
23.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
23.2
vs History
53
vs Industry
19
Median 3Y
21.5
Median 5Y
23
Industry
10.5
More Details
42
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
42
vs History
31
vs Industry
2
Median 3Y
35.9
Median 5Y
35.6
Industry
6.1
Forward
33.3
More Details
56.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
56.2
vs History
34
vs Industry
1
Median 3Y
49.5
Median 5Y
45.5
Industry
6.6
Forward
43.3
More Details
61.6
EV/OCF
EV/OCF
Enterprise Value to OCF
61.6
vs History
49
vs Industry
3
Median 3Y
52.4
Median 5Y
59.7
Industry
8.8
More Details
101.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
101.3
vs History
30
vs Industry
2
Median 3Y
81.4
Median 5Y
68.1
Industry
6.8
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
58
vs Industry
45
Median 3Y
2.1
Median 5Y
3.8
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Celltrion Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Celltrion Inc
KRX:068270
48.1T KRW 12.4 65.2 42 56.2
IL
Can Fite Biopharma Ltd
TASE:CANF
154.4T ILS 56 284 545.2 -3 865 260.4 -3 793 003.7 -3 784 560.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 004 331.7 -161 617.5 -196 255.2 -194 015.7
US
Abbvie Inc
NYSE:ABBV
388.9B USD 6.5 165.6 16.1 22.8
US
Amgen Inc
NASDAQ:AMGN
175.1B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
152.3B USD 5.2 18.8 12.6 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 10 31.8 23.4 24.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 071.8 -528.7 -575.7 -560.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.9 19.1
AU
CSL Ltd
ASX:CSL
83.9B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.9B USD 15.2 1 122.1 151.2 183.4
P/S Multiple
Revenue Growth P/S to Growth
KR
Celltrion Inc
KRX:068270
Average P/S: 8 208 273.8
12.4
17%
0.7
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 284 545.2
140%
402 032.5
FR
Pharnext SCA
OTC:PNEXF
34 004 331.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 071.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.2
46%
0.3
P/E Multiple
Earnings Growth PEG
KR
Celltrion Inc
KRX:068270
Average P/E: 183.1
65.2
52%
1.3
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 865 260.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 617.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 122.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Celltrion Inc
KRX:068270
Average EV/EBITDA: 36.6
42
35%
1.2
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 793 003.7 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
151.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Celltrion Inc
KRX:068270
Average EV/EBIT: 44.1
56.2
57%
1
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 784 560.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 015.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
183.4
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.